Almufleh A, et al. - Researchers performed a comparison of proton pump inhibitors (PPIs) to histamine 2 receptor antagonists (H2RAs) in patients on dual antiplatelet therapy (DAPT) in terms of GI complications, major adverse cardiovascular events (MACE), and high on-treatment platelet reactivity (HTPR). Ten randomized controlled trials were eligible for analysis in this study. Findings reveal that, vs H2RAs, PPIs provide better gastroprotection in these patients. However, PPIs are associated with HTPR, without a significant difference demonstrated in MACE. Available data thus justify using PPIs in select patients on DAPT considered at risk for GI complications.